open access

Vol 21, No 6 (2016)
Original research articles
Published online: 2016-11-01
Submitted: 2016-01-02
Get Citation

Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Zbigniew Szutkowski, Andrzej Kawecki, Andrzej Jarząbski, Zofia Laskus, Romuald Krajewski, Wojciech Michalski, Paweł Kukołowicz
DOI: 10.1016/j.rpor.2016.08.001
·
Rep Pract Oncol Radiother 2016;21(6):537-543.

open access

Vol 21, No 6 (2016)
Original research articles
Published online: 2016-11-01
Submitted: 2016-01-02

Abstract

Aim

The goal of this prospective study was to assess the effectiveness of a hypofractionated accelerated regime in treatment of the larynx cancer.

Background

Multiple radiotherapy delivery regimes are used for treatment of the larynx cancer. Hypofractionated regimes could provide similar results with reduced use of radiotherapy facilities.

Material and methods

223 patients with squamous cell carcinoma of the upper or middle larynx have been treated with 63[[ce:hsp sp="0.25"/]]Gy delivered in 28 fractions of 2.25[[ce:hsp sp="0.25"/]]Gy during 38 days, 5 fractions per week. The study endpoints were overall survival, progression-free survival, early and late treatment toxicity. Standard and accelerated radiotherapy groups from the study published by Hliniak et al.[[ce:cross-ref id="crf0065" refid="bib0275"]]20 served as controls.

Results

Five-year actuarial overall survival was 87.5% in the study group, 84.5% in the control group receiving accelerated radiotherapy (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 6 fractions per week) and 86.2% in the control group (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 5 fractions per week). Five-year progression-free survival was 73.6%, 77.2% and 66.2%, respectively. Overall, treatment toxicity and complication rates did not differ between the study group and the control groups.

Conclusions

The hypofractionated accelerated radiotherapy protocol using 5 fractions per week reduced the use of radiotherapy facilities. There was no significant difference in overall survival and progression-free survival between the study and control groups treated with accelerated or standard radiotherapy.

Abstract

Aim

The goal of this prospective study was to assess the effectiveness of a hypofractionated accelerated regime in treatment of the larynx cancer.

Background

Multiple radiotherapy delivery regimes are used for treatment of the larynx cancer. Hypofractionated regimes could provide similar results with reduced use of radiotherapy facilities.

Material and methods

223 patients with squamous cell carcinoma of the upper or middle larynx have been treated with 63[[ce:hsp sp="0.25"/]]Gy delivered in 28 fractions of 2.25[[ce:hsp sp="0.25"/]]Gy during 38 days, 5 fractions per week. The study endpoints were overall survival, progression-free survival, early and late treatment toxicity. Standard and accelerated radiotherapy groups from the study published by Hliniak et al.[[ce:cross-ref id="crf0065" refid="bib0275"]]20 served as controls.

Results

Five-year actuarial overall survival was 87.5% in the study group, 84.5% in the control group receiving accelerated radiotherapy (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 6 fractions per week) and 86.2% in the control group (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 5 fractions per week). Five-year progression-free survival was 73.6%, 77.2% and 66.2%, respectively. Overall, treatment toxicity and complication rates did not differ between the study group and the control groups.

Conclusions

The hypofractionated accelerated radiotherapy protocol using 5 fractions per week reduced the use of radiotherapy facilities. There was no significant difference in overall survival and progression-free survival between the study and control groups treated with accelerated or standard radiotherapy.

Get Citation

Keywords

Carcinoma; Squamous cell; Larynx; Radiotherapy; Hypofractionated radiotherapy; Accelerated radiotherapy

About this article
Title

Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 21, No 6 (2016)

Pages

537-543

Published online

2016-11-01

DOI

10.1016/j.rpor.2016.08.001

Bibliographic record

Rep Pract Oncol Radiother 2016;21(6):537-543.

Keywords

Carcinoma
Squamous cell
Larynx
Radiotherapy
Hypofractionated radiotherapy
Accelerated radiotherapy

Authors

Zbigniew Szutkowski
Andrzej Kawecki
Andrzej Jarząbski
Zofia Laskus
Romuald Krajewski
Wojciech Michalski
Paweł Kukołowicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl